Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab in Relapsed or Refractory Multiple Myeloma
NCT03761108Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Mar 2033
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, open-label trial of linvoseltamab in multiple myeloma (MM) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events at 5 years and 5 more. Started Jan 2019; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03761108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761108.